Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

17:33
10/09/16
10/09
17:33
10/09/16
17:33

Bristol-Myers reports data from CheckMate-016 kidney cancer study

Bristol-Myers Squibb announced updated results from the Phase 1 CheckMate -016 trial, which evaluated the safety and tolerability of Opdivo at different doses as part of a regimen with Yervoy, sunitinib or pazopanib in previously treated and treatment-naive patients with metastatic renal cell carcinoma. These updated results include findings for the Opdivo and Yervoy combinations with approximately two years of follow-up, which showed the overall response rate was 40.4% in both arms. Of the 38 responders in both treatment arms, 39.5% had an ongoing response, with a median duration of response of 20.4 months in the Opdivo 3 mg/kg plus Yervoy 1 mg/kg arm and 19.7 months in the Opdivo 1 mg/kg plus Yervoy 3 mg/kg arm. The overall survival rate at 12 months was 81% and 85% for Opdivo 3 mg/kg plus Yervoy 1 mg/kg arm and Opdivo 1 mg/kg plus Yervoy 3 mg/kg arm, respectively, and at 24 months was 67% and 70%, respectively. There were fewer Grade 3/4 treatment-related adverse events reported in the Opdivo 3 mg/kg plus Yervoy 1 mg/kg arm -- 38.3% -- than with Opdivo 1 mg/kg plus Yervoy 3 mg/kg arm -- 61.7%. Discontinuations due to treatment-related AEs included five and 13 patients in the Opdivo 3 mg/kg and Yervoy 1 mg/kg and Opdivo 1 mg/kg and Yervoy 3 mg/kg arms, respectively. Based on these results, further development of the Opdivo 1 mg/kg and Yervoy 3 mg/kg regimen was not pursued.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

V

Visa

$102.90

-2.665 (-2.52%)

14:50
09/25/17
09/25
14:50
09/25/17
14:50
Options
Bullish option play opened in Visa as shares slump »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RHT

Red Hat

$105.41

-0.89 (-0.84%)

14:49
09/25/17
09/25
14:49
09/25/17
14:49
Options
Red Hat options imply 10.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

APRN

Blue Apron

$5.47

0.28 (5.40%)

14:45
09/25/17
09/25
14:45
09/25/17
14:45
Options
Blue Apron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$44.37

0.125 (0.28%)

, PCLN

Priceline

$1,862.13

-4.22 (-0.23%)

14:42
09/25/17
09/25
14:42
09/25/17
14:42
Hot Stocks
Analysts trim TripAdvisor estimates on increasing online travel concerns »

Shares of TripAdvisor…

TRIP

TripAdvisor

$44.37

0.125 (0.28%)

PCLN

Priceline

$1,862.13

-4.22 (-0.23%)

TRVG

trivago

$10.70

-0.04 (-0.37%)

EXPE

Expedia

$145.77

2.65 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.51

-1.185 (-1.43%)

14:36
09/25/17
09/25
14:36
09/25/17
14:36
Conference/Events
Dycom management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

DY

Dycom

$81.56

-1.13 (-1.37%)

14:35
09/25/17
09/25
14:35
09/25/17
14:35
Options
Dycom put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

14:31
09/25/17
09/25
14:31
09/25/17
14:31
Technical Analysis
Technical View: Amazon.com falls, topping process confirmed »

The shares are down 2.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

DIS

Disney

$99.37

0.77 (0.78%)

14:27
09/25/17
09/25
14:27
09/25/17
14:27
Recommendations
Disney analyst commentary  »

Disney approach to price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ESV

Ensco

$5.77

0.53 (10.11%)

14:25
09/25/17
09/25
14:25
09/25/17
14:25
Options
Ensco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

NFLX

Netflix

$187.35

-1.43 (-0.76%)

14:21
09/25/17
09/25
14:21
09/25/17
14:21
Technical Analysis
Technical View: Netflix trades near lows of the day »

The shares are down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

14:17
09/25/17
09/25
14:17
09/25/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/25/17
09/25
14:16
09/25/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GREK

Global X MSCI Greece ETF

$9.18

-0.635 (-6.47%)

14:10
09/25/17
09/25
14:10
09/25/17
14:10
Options
MSCI Greek Fund puts are active as shares falter »

MSCI Greek Fund puts are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.30

-0.11 (-0.82%)

, NVDA

Nvidia

$179.00

-1.76 (-0.97%)

14:08
09/25/17
09/25
14:08
09/25/17
14:08
Hot Stocks
AMD, NVIDIA fall after Intel unveils next generation of core processors »

Shares of AMD (AMD) and…

AMD

AMD

$13.30

-0.11 (-0.82%)

NVDA

Nvidia

$179.00

-1.76 (-0.97%)

INTC

Intel

$37.18

-0.02 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

  • 22

    Oct

HLF

Herbalife

$67.51

-0.06 (-0.09%)

14:06
09/25/17
09/25
14:06
09/25/17
14:06
Hot Stocks
FTC grants Carl Icahn clearance for additional Herbalife purchases »

The Federal Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$80.52

4.45 (5.85%)

14:05
09/25/17
09/25
14:05
09/25/17
14:05
Options
YY call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
09/25/17
09/25
14:05
09/25/17
14:05
General news
Treasury Option Action: heavy put spread demand at the short-end »

Treasury Option Action:…

RCII

Rent-A-Center

$10.80

-0.07 (-0.64%)

13:55
09/25/17
09/25
13:55
09/25/17
13:55
Options
Rent A Center put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
09/25/17
09/25
13:55
09/25/17
13:55
Conference/Events
Senate Finance Committee holds a hearing »

The Committee holds a…

GS

Goldman Sachs

$230.10

-0.93 (-0.40%)

13:54
09/25/17
09/25
13:54
09/25/17
13:54
Periodicals
Symphony to raise $100M to expand, The Information says »

Goldman Sachs-backed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 17

    Oct

  • 22

    Oct

AMDA

Amedica

$0.33

0.005 (1.56%)

13:50
09/25/17
09/25
13:50
09/25/17
13:50
Downgrade
Amedica rating change  »

Amedica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SCWX

SecureWorks

$12.57

0.15 (1.21%)

13:47
09/25/17
09/25
13:47
09/25/17
13:47
Hot Stocks
Breaking Hot Stocks news story on SecureWorks »

ETF Managers Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$36.59

0.81 (2.26%)

13:45
09/25/17
09/25
13:45
09/25/17
13:45
Options
Devon Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

13:45
09/25/17
09/25
13:45
09/25/17
13:45
General news
Treasury Action: coupon supply commences Tuesday »

Treasury Action: coupon…

ADP

ADP

$108.16

1.37 (1.28%)

13:43
09/25/17
09/25
13:43
09/25/17
13:43
Hot Stocks
Pershing: ADP overstates shareholder return during CEO's tenure »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.